DGAP-News: Defense Therapeutics Inc. / Keyword (s): Miscellaneous
13.12.2021 / 08:30
The sender is solely responsible for the content of this advertisement.



Vancouver, British Columbia, Canada, December 13e, 2021 – Defense Therapeutics Inc. (“Defense“or the”Society“), a biotechnology company focused on the development of vaccines and therapies against cancer and infectious diseases, is pleased to announce that its AccumMT The platform can greatly improve the delivery of Cas9 to target cells, which would have a significant positive impact on the CRISPR industry.

CRISPR technology offers the potential to transform medicine, enabling both the treatment or prevention of many diseases by deleting or inserting genes in a targeted manner. This technology is at the heart of the biotechnology industry because it can be used to treat multiple diseases such as cancer, viral diseases (HIV and hepatitis B) as well as several genetic disorders. The essence of this technology is simple and requires two important tools: 1) a piece of genetic material to guide the editing process, and 2) the co-administration of a Cas protein to cut / edit DNA. Of all the Cas proteins currently identified, Cas9 is the most widely used by scientists because it can easily find and bind to almost any desired target sequence, simply by donating a piece of RNA to guide it in its search.

The administration of the Cas9 protein instead of a DNA coding sequence offers the advantage of decreasing the off-target activity of Cas9. Current and existing protein delivery tools available today are inefficient at delivering proteins inside the nucleus of target cells. More precisely, any protein delivered ends up being trapped and degraded in small endosome-lysosome vesicles. Therefore, the cytosolic Cas9 pool is of low amplitude, which makes it difficult to reach the nucleus for efficient DNA editing activity. As such, multiple deliveries must be attempted to achieve sufficient Cas9 nuclear material.

The AccumMT platform is designed to accumulate a given molecule in target cells. The Defense team tested AccumMTability to improve the delivery of Cas9 to cells. The results obtained, with a single AccumMT dose and without any added use of a complex lipid formulation, are amazing. Accum accumulationMT-The Cas9 bound inside the nucleus of cells was at least 9 times higher than free Cas9 when added to mammalian cells in vitro.

“We successfully provide another strong example of the versatility and power of AccumMT is to provide critically important protein. This observation is essential for Defense because it paves the way for strategic partnerships with large pharmaceutical companies in the field seeking to improve their approach to CRISPR / Cas9 editing ”, declares Mr. Plouffe, CEO of Defense Therapeutics.

With these astonishing data in hand, Defense will actively seek to partner with major players in the field in order to advance CRISPR-based treatments designed for specific indications.

According to the report published by Fior Markets, the global gene editing market is expected to grow from USD 4.2 billion in 2020 to USD 13 billion by 2028, at a CAGR of 15.2% during the period of forecast 2021-2028.

About the Defense:
Defense Therapeutics is a publicly traded biotechnology company working to design next generation ADC vaccines and products using its proprietary platform. The heart of the Defense Therapeutics platform is ACCUMMT technology, which enables the precise delivery of vaccine antigens or ADC in their intact form to target cells. As a result, increased efficiency and potency can be achieved against catastrophic diseases such as cancer and infectious diseases.

For more information:
Sébastien Plouffe, President, Chief Executive Officer and Director
Phone. : (514) 947-2272
[email protected]

Caution regarding “forward-looking” information

This press release includes certain statements which may be considered “forward-looking statements”. All statements in this press release, other than statements of historical fact, which deal with events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements which are not historical fact and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends to”. “,” Estimates “,” projects “,” potential “and similar expressions, or that events or conditions” will “,” would “,” could “,” could “or” should “occur. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and actual results may differ materially from those of forward-looking statements. Factors that could cause actual results to differ materially from those of forward-looking statements include regulatory actions, market prices and the continued availability of capital and financing, as well as general economic, market or Business. Investors are cautioned that these statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the management of the Company on the date the statements are made. Except as required by applicable securities laws, the Company assumes no obligation to update these forward-looking statements in the event that the beliefs, estimates or opinions of management, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

13.12.2021 Distribution of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The sender is solely responsible for the content of this advertisement.

DGAP’s distribution services include regulatory announcements, financial / corporate news, and press releases.
Archives on

Source link

Sara H. Byrd